The Effect of Vancomycin and Third-Generation Cephalosporins on Prevalence of Vancomycin-Resistant Enterococci in 126 U.S. Adult Intensive Care Units

Established in 1927 by the American College of Physicians

Abstract/Editors' Note | Full Text | PDF

FIGURES/TABLES SUMMARY PAGE

PowerPoint slides are available for most Figures at Annals.org

The Effect of Vancomycin and Third-Generation Cephalosporins on Prevalence of Vancomycin-Resistant Enterococci in 126 U.S. Adult Intensive Care Units

View this table:

[in a new window]

Table 1. Class, Grouping, and Defined Daily Dose of Antimicrobial Agents

View this table:

[in a new window]

Table 2. Selected Characteristics (Median Values) of 126 Intensive Care Units, according to Unit Type

View larger version (13K):

[in a new window]

Figure. Correlation of the rate of parenteral vancomycin (defined daily doses per 1000 patient-days) and the prevalence of vancomycin-resistant enterococci (percentage of enterococci that are vancomycin resistant) in 126 intensive care units.P values were determined for the Spearman correlation coefficient (r = 0.44 [95% CI, 0.29 to 0.57]) and weighted linear regression (parameter estimate = 0.08; P = 0.001).

View this table:

[in a new window]

Table 3. Independent Predictors of Intensive Care Unit–Specific Prevalence of Vancomycin-Resistant Enterococci